2[1]Banchereau J,Schuler-Thurner B,Palucka AK,Schuler G.Dendritic cells as vectors for therapy.Cell 2001;106:271-274
3[2]Whiteside TL,Odoux C.Dendritic cell biology and cancer therapy.Cancer Immunol Immunother 2004;53:240-248
4[3]Schuler G,Schuler-Thurner B,Steinman RM.The use of dendritic cells in cancer immunotherapy.Curr Opin Immunol2003;15:138-147
5[4]Mocellin S,Rossi CR,Lise M,Nitti D.Colorectal cancer vaccines:principles,results,and perspectives.Gastroenterology2004;127:1821-1837
6[5]Audibert F.Adjuvants for vaccines,a quest.Int Imrnunopharmacol2003;3:1187-1193
7[6]Menoret A,Patry Y,Burg C,Le Pendu J.Co-segregation of tumor immunogenicity with expression of inducible but not constitutive hsp70 in rat colon carcinomas.J Immunol 1995;155:740-747
8[7]Okamoto M,Tazawa K,Kawagoshi T,Maeda M,Honda T,Sakamoto T,Tsukada K.The combined effect against colon-26cells of heat treatment and immunization with heat treated colon-26 tumour cell extract.Int J Hyperthermia 2000;16:263-273
9[8]Lutz MB,Kukutsch N,Ogilvie AL,Rossner S,Koch F,Romani N,Schuler G.An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.J Immunol Methods 1999;223:77-92
10[9]Miyahira Y,Murata K,Rodriguez D,Rodriguez JR,Esteban M,Rodrigues MM,Zavala F.Quantification of antigen specific CD8+T cells using an ELISPOT assay.J Immunol Methods 1995;181:45-54
3Liu SH, Zhang M, Zhang WG, et al. Strategies of antigen specific T-cell-based immunotherapy for cancer. Cancer Biother Radiopharm,2005, 20(5) :491.
4Zhang Y, Zhang Y, Wang Y, et al. Development of dendritic cells in vitro from murine fetal liver-derived lineage phenotype-negative c-kit+ hematopoietic progenitor cells [J]. Blood, 2000,95( 1 ) : 138-146.
5Shortman K, Liu YJ. Mouse and human dendritic cell subtypes [J]. Nat Rev Immunol, 2002,2(3) : 151-161.
6O'Connell PJ, Li W, Wang Z, et al. Immature and mature CD8alpha+ dendritic cells prolong the survival of vascularized heart allografts [J]. J Immunol, 2002,168( 1 ) : 143-154.
7Parajuli P, Mosley RL, Pisarev V, et al. Fh3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets [J]. Exp Hematol, 2001,29(10) : 1185-1193.
8Rosenzwajg M, Camus S, Guigon M, et al. The influence of interleukin (IL)-4, IL-13, and Flt3 ligand on human dendritic cell differentiation from eord blood CD34+ progenitor cells [J]. Exp Hematol, 1998,26( 1 ) : 63-72.
9Miller G, Pillarisetty VG, Shah AB, et al. Murine Fh3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties [J]. J Immunol, 2003,170(7): 3554-3564.
10Xu L, Duan LN, Cao KY, et al. Predominant immature CD8alpha + dendritic cells prevent graft-versus-host disease but do not increase the risk of leukemia recurrence [J]. Eur J Haematol, 2007,78(3) :235-245.
